Araki Tsuyoshi, Yamasue Hidenori, Sumiyoshi Tomiki, Kuwabara Hitoshi, Suga Motomu, Iwanami Akira, Kato Nobumasa, Kasai Kiyoto
Department of Neuropsychiatry, Graduate School of Medicine, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan.
Prog Neuropsychopharmacol Biol Psychiatry. 2006 Mar;30(2):204-8. doi: 10.1016/j.pnpbp.2005.10.015. Epub 2005 Nov 21.
The present study was performed to determine if perospirone, a novel antipsychotic drug with D2/5-HT2A antagonist and partial 5-HT1A agonist properties, would improve memory organization in twelve patients with chronic schizophrenia. Switching to equivalent dose of perospirone from prior antipsychotic medication was associated with a significant improvement in indices of verbal memory organization of the Auditory Verbal Learning Test. Negative symptoms and extrapyramidal side effects were also ameliorated after switching to perospirone. The distinct cognitive enhancement profile of perospirone may be attributable to its partial 5-HT1A agonist action.
本研究旨在确定一种具有D2/5-HT2A拮抗剂和部分5-HT1A激动剂特性的新型抗精神病药物——哌罗匹隆,是否能改善12例慢性精神分裂症患者的记忆组织。从先前的抗精神病药物转换为等效剂量的哌罗匹隆,与听觉词语学习测试的言语记忆组织指标显著改善相关。转换为哌罗匹隆后,阴性症状和锥体外系副作用也有所改善。哌罗匹隆独特的认知增强特性可能归因于其部分5-HT1A激动剂作用。